Compass Therapeutics Future Growth

Future criteria checks 2/6

Compass Therapeutics is forecast to grow earnings and revenue by 50.7% and 66.1% per annum respectively while EPS is expected to grow by 52.5% per annum.

Key information

50.7%

Earnings growth rate

52.5%

EPS growth rate

Biotechs earnings growth	24.7%
Revenue growth rate	66.1%
Future return on equity	n/a
Analyst coverage	Good
Last updated	03 Jun 2024

Recent future growth updates

Recent updates

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Jun 05

We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Feb 13

Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Sep 20

Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial

Oct 11

Earnings and Revenue Growth Forecasts

NasdaqCM:CMPX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	69	-45	N/A	-59	7
12/31/2025	5	-71	N/A	-55	7
12/31/2024	N/A	-55	N/A	-48	7
3/31/2024	N/A	-45	-42	-42	N/A
12/31/2023	N/A	-42	-41	-41	N/A
9/30/2023	N/A	-41	-39	-39	N/A
6/30/2023	N/A	-43	-44	-44	N/A
3/31/2023	N/A	-40	-38	-38	N/A
12/31/2022	N/A	-39	-34	-34	N/A
9/30/2022	N/A	-41	-29	-28	N/A
6/30/2022	N/A	-35	-22	-21	N/A
3/31/2022	N/A	-82	-24	-22	N/A
12/31/2021	N/A	-82	-22	-20	N/A
9/30/2021	N/A	-78	-23	-22	N/A
6/30/2021	N/A	-81	-26	-25	N/A
3/31/2021	N/A	-31	-25	-25	N/A
12/31/2020	N/A	-29	-27	-27	N/A
9/30/2020	N/A	-28	-26	-26	N/A
6/30/2020	N/A	-27	-26	-25	N/A
3/31/2020	N/A	-30	-29	-29	N/A
12/31/2019	N/A	-35	-32	-32	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CMPX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CMPX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CMPX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CMPX's revenue (66.1% per year) is forecast to grow faster than the US market (8.6% per year).

High Growth Revenue: CMPX's revenue (66.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CMPX's Return on Equity is forecast to be high in 3 years time

Compass Therapeutics Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target increased to US$9.46

Price target increased to US$9.67

Price target decreased to US$8.86

Recent updates

We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business Growth

Compass Therapeutics, Inc. Announces Management Changes

Compass Therapeutics to Present Phase 1 Data for CTX-471, a Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

Compass Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Compass Therapeutics, Inc. Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated

Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

New minor risk - Shareholder dilution

We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash Wisely

Compass Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 9, 2024

Compass Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 9, 2024

Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In Growth

Ankyra Therapeutics Names Robert V. Tighe as Chief Scientific Officer

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Co-Founder recently bought US$80k worth of stock

Co-Founder recently bought US$77k worth of stock

Compass Therapeutics, Inc. Appoints David Wurzer as Class III Director, Member and Chairman of the Audit Committee

Price target increased to US$9.46

Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer

Compass Therapeutics, Inc. Announces That the First Patient Has Been Dosed in the Phase 1B Study of CTX-471 in Combination with Keytruda®, Merck’S Anti-PD-1 Therapy

President & COO recently sold US$97k worth of stock

Price target increased to US$9.67

High number of new and inexperienced directors

Compass Therapeutics, Inc. announced that it expects to receive $80.25 million in funding from a group of investors

Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial

High number of new and inexperienced directors

Compass Therapeutics, Inc. Announces Resignation of Stephen Squinto as Member of the Board of Directors, Effective August 31, 2022

High number of new and inexperienced directors

Co-Founder recently bought US$61k worth of stock

Co-Founder recently bought US$50k worth of stock

Compass Therapeutics, Inc. Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers

High number of new and inexperienced directors

Price target decreased to US$8.86

Compass Therapeutics Announces Management Appointments

Compass Therapeutics, Inc. Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting

Compass Therapeutics, Inc. Announces Resignation of Brett Kaplan of the Board of Directors

Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)

High number of new and inexperienced directors

Compass Therapeutics, Inc. (OTCPK:CMPX) entered into a definitive merger agreement to acquire TRIGR Therapeutics, Inc. for $45.2 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies